Cytometry A Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective

[tetano]

Cytometry A


. 2020 Jun 7.
doi: 10.1002/cyto.a.24047. Online ahead of print.
Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective


Henning Ulrich ¹ , Micheli M Pillat ² , Attila T?rnok ^{3 4 5}



Affiliations

• PMID: 32506725
• DOI: 10.1002/cyto.a.24047

Abstract

SARS-CoV-2 pandemic and recurrent dengue epidemics in tropical countries have turned into a global health threat. While both virus-caused infections may only reveal light symptoms, they can also cause severe diseases. Here, we review the possible antibody-dependent enhancement (ADE) occurrence, known for dengue infections, when there is a second infection with a different virus strain. Consequently, preexisting antibodies do not neutralize infection, but enhance it, possibly by triggering Fcγ receptor-mediated virus uptake. No clinical data exist indicating such mechanism for SARS-CoV-2, but previous coronavirus infections or infection of SARS-CoV-2 convalescent with different SARS-CoV-2 strains could promote ADE, as experimentally shown for antibodies against the MERS-CoV or SARS-CoV spike S protein. ? 2020 International Society for Advancement of Cytometry.

Keywords: 2019-nCoV; COVID-19; SARS-CoV-2; antibody-dependent enhancement; coronavirus.



? 2020 International Society for Advancement of Cytometry.